Monitoring immune-checkpoint blockade: response evaluation and biomarker development (Q38666241)

5 September 2017

1 reference

title

Monitoring immune-checkpoint blockade: response evaluation and biomarker development (English)

1 reference

5 September 2017

0 references

4

F Stephen Hodi

1 reference

5 September 2017

Mizuki Nishino

1

1 reference

5 September 2017

Nikhil H Ramaiya

series ordinal

2

1 reference

5 September 2017

Hiroto Hatabu

series ordinal

3

1 reference

5 September 2017

language of work or name

English

0 references

publication date

27 June 2017

1 reference

Nature Reviews Clinical Oncology

5 September 2017

published in

1 reference

CD28/B7 system of T cell costimulation

5 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

Cancer immunotherapy and immune-related response assessment: The role of radiologists in the new arena of cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

Reporting results of cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

Revised RECIST guideline version 1.1: What oncologists want to know and what radiologists need to know

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

Pseudoprogression and Immune-Related Response in Solid Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

State of the art: Response assessment in lung cancer in the era of genomic medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

CT tumor volume measurement in advanced non-small-cell lung cancer: Performance characteristics of an emerging clinical tool

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

Nivolumab in previously untreated melanoma without BRAF mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

Pembrolizumab versus Ipilimumab in Advanced Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

Immunotherapy response assessment in neuro-oncology: a report of the RANO working group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

Pembrolizumab for the treatment of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A Review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

Towards the introduction of the 'Immunoscore' in the classification of malignant tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

PD-1 blockade induces responses by inhibiting adaptive immune resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

The immune landscape of human tumors: Implications for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

Predictive Markers for the Efficacy of Anti-PD-1/PD-L1 Antibodies in Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

Comprehensive molecular profiling of lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

Neoantigens in cancer immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

Genetic basis for clinical response to CTLA-4 blockade in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

The proportion of circulating CD45RO+CD8+ memory T cells is correlated with clinical response in melanoma patients treated with ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

Tumor volume decrease at 8 weeks is associated with longer survival in EGFR-mutant advanced non-small-cell lung cancer patients treated with EGFR TKI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: developing criteria to continue therapy beyond RECIST progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or Gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

An Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

21 January 2018

1 reference

PubMed Central

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5650537

Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma.

4 November 2018

1 reference

PubMed Central

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5650537

Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study

4 November 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

PD-L1 Testing in Cancer: Challenges in Companion Diagnostic Development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.88

10.1038/NRCLINONC.2017.88

31 March 2020

Identifiers

DOI

1 reference

Dimensions Publication ID

5 September 2017

1086289497

0 references

PMC publication ID

5650537

0 references

1 reference